Assessment of efficacy and adverse events following SARS-CoV-2 cohort of subjects previously infected with COVID-19
Study code
NBR112
Lead researcher
Dr James Thaventhiran
Study type
Participant re-contact
Institution or company
MRC
Researcher type
Academic
Speciality area
Infection, COVID
Summary
Currently it is unclear if existing COVID-19 immunity generated by prior exposure increases the chance of adverse reactions COVID-19 vaccination or a blunting of vaccine efficacy. We are in a unique position to assess this as we have recently collected blood samples from a cohort of subjects that will be imminently offered the vaccine. We will quantitatively measure adaptive immunity prior to vaccination in these subjects and assess the correlation of this with either vaccine adverse effects or vaccine efficacy.
Participation: For this study we had 49 participants from the COVID-19 BioResource take part by providing a blood sample and completing a health & lifestyle questionnaire.
Organisation: This study is organised by Dr James Thaventhiran from the MRC Toxicology Unit, Cambridge